A high, unmet need — Chronic, localized pain relief

All marketed local anesthetics inhibit tissue regeneration, and therefore are not warranted for use beyond 2 hrs. There are no long-lasting local pain relief agents in the market and all existing anesthetics affect motor function. In addition, there is high demand for local, long standing sensory symptoms relief in many areas of medicine.

 

The dSentz solution

dSentz has developed a first-in-class anesthetic agent that delivers fast, long-lasting pain relief for patients. It was shown to exert neuro-inflammatory mediated relief through a known mechanism of action. For the first time, a local anesthetic does not inhibit tissue regeneration, but rather provides an immediate and long-lasting pain relief as well as immune mediation. Utilizing its favorable safety profile, multiple applications for the treatment of pain are possible. This opens the door for indications that are currently contra-indicated with current standard of care such as safe intramuscular administration.

 

Pre-clinical work has thus far focused on DS-101 effects in multiple dry eye and pain models. We have also established a novel mechanism of action (MOA) with which topical administration of DS-101 relieves pain. We demonstrated that despite its long duration of effect, and unlike other topical anesthetics, it does not inhibit wound healing, and therefore can be used for the treatment of both acute and chronic pain.   We also established, for the first time, the dual effect of DS-101: its ability to control both neurally-mediated pain and inflammation. This offers both direct pain control and a treatment for one of its underlying causes through immune modulation.